Drug Tariff Listing

Advanced Medical Solutions Grp PLC
18 December 2003


For Release:  7 am                                 Thursday, 18 December, 2003


                      Advanced Medical Solutions Group plc
          Announces Drug Tariff listing of advanced woundcare products
           & strengthening of its UK Sales & Marketing infrastructure


Winsford, UK: Advanced Medical Solutions (AIM: AMS), the global woundcare
technology company, today announces that it has received Drug Tariff listing for
a range of its advanced woundcare products, including its seaweed based alginate
dressing which promotes fast wound healing and provides cosmetic benefits. These
products will be sold directly into the National Health Service (NHS) through
the Company's strengthened UK Sales and Marketing infrastructure.



The Drug Tariff, which is updated monthly and compiled on behalf of the
Department of Health for use by healthcare professionals throughout England and
Wales, provides a catalogue of medical products which are known to be safe, good
quality, appropriate for prescribing by a GP (or nurse) and cost effective.



The NHS currently spends an estimated £100 million on advanced woundcare
dressings per year of which a major contribution is attributable to products
listed on the Drug Tariff.



Drug Tariff listing allows AMS to sell its range of woundcare products directly
into the NHS through the Group's MedLogic sales & marketing infrastructure,
which was acquired in 2002. A key synergy of AMS' acquisition of MedLogic was to
leverage its sales resource and relationships at various levels in the NHS to
sell the AMS woundcare range.



The Company will focus its direct selling efforts on providing a generic
advanced woundcare range to the NHS whilst continuing to sell its differentiated
woundcare products through its major partners under their leading brands.



Following the receipt of CE mark approval for AMS' LiquiBandTM Surgical product,
which was announced earlier this week, the MedLogic sales and marketing team has
started selling LiquiBandTM Surgical into hospital operating theatres. The Drug
Tariff listing announced today allows a further opportunity to leverage these
relationships.



Commenting on this announcement, Dr Don Evans, CEO of AMS stated:



'I am delighted that we have obtained Drug Tariff listing which opens up a new
and exciting opportunity to exploit further our direct UK sales and marketing
team.



The recent success we have achieved in growing our UK tissue adhesives business
indicates that advantage should be taken to broaden this approach to also
include our advanced woundcare products.



Over the last few years AMS has been heavily dependent on the commitment, focus
and success of our partners to commercialise our technology and to deliver sales
growth.  Now AMS is able to increase  its influence over its own sales
activities and to decrease its dependence on these key partnerships.  By
interfacing directly with end users in our home market, we are in an ideal
position to achieve customer driven innovation benefiting both AMS and our
international partners in the future.'



                                    - ENDS -



For further information, please contact:


Advanced Medical Solutions Group plc          Tel : [phone]

Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                       Tel: [phone]
Tim Anderson, Mary-Jane Johnson





Notes to Editors:



Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.



Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.



In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.



The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to hospitals or
through distributors.



AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf.




                      This information is provided by RNS
            The company news service from the London Stock Exchange   D

MSCEAXAXFEDDFFE